MDGL

Madrigal Pharmaceuticals, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$425.21

Price (1 Year)

$598.91 $399.63

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %4.4 / %30
Non-compliant assets / Total market cap %10.6 / %30
Non-compliant revenue / Total income %2.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

Website

Analysis (Turkish): MDGL Hissesi Caiz mi, Helal mi? Madrigal Pharmaceuticals, Inc. Katılım Analizi